Drug-Eluting Balloon Catheters Market Analysis and Forecast to 2031: By Product (Coronary Artery Disease, Peripheral Vascular Disease), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories), and Region

Drug-Eluting Balloon Catheters Market Analysis and Forecast to 2031: By Product (Coronary Artery Disease, Peripheral Vascular Disease), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories), and Region

The global vacuum bearing market was valued at US$ 400 million in 2021 and it is anticipated to grow up to US$ 1.1 billion by 2031, at a CAGR of 10.7% during the forecast period.

A drug-eluting balloon is a non-stent technology in which the vessel wall processes the effective homogeneous delivery of anti-proliferative drugs via an inflated balloon. Healthcare infrastructure has undergone significant changes in the last decade as technology has proliferated and healthcare research has expanded significantly. Rising obesity, an ageing population, and an increase in the prevalence of coronary artery disease are some of the factors driving demand for drug-eluting balloon catheters. When stents are used in conjunction with a balloon catheter, they are referred to as balloon expandable stents, as opposed to self-expandable stents, which are typically made of nitinol alloy.
Global Drug-Eluting Balloon Catheters Market Scope and Report Structure
Market Drivers and Trends
The increasing prevalence of coronary artery disease among people all over the world is the primary driver of the industry's growth. For example, according to the World Health Organization, approximately 3.8 million men and 4.4 million women will die from coronary heart disease. Furthermore, the number of deaths between the ages of 15 and 59 is approximately 1332 million, and the number of deaths over the age of 60 is approximately 5825 million. Furthermore, according to the Centers for Disease Control and Prevention, coronary heart disease will be the most common type of heart disease in upcoming years, killing 382,820 people globally.

Furthermore, the industry's growth will be driven by increasing prevalence of diabetes. According to the World Health Organization's October 2018 report, diabetes is responsible for approximately 1.6 million deaths worldwide. According to the Centers for Disease Control and Prevention, diabetes has affected 537 million adults (20-79 years) worldwide in 2021, accounting for one in every ten people. China has the most diabetics in the world, with approximately 141 million people suffering from the disease. Diabetes is expected to affect approximately 174 million people in China by 2045. These factors are expected to drive the growth of the global Drug-Eluting Balloon Catheters Market.
Market Restraints and Challenges
Over the period, the high risk of infections associated with drug-eluting balloon catheters is expected to hinder growth in the global Drug-Eluting Balloon Catheters Market. Despite increasing product adoption factors such as catheterization procedures and balloon catheters may have a negative impact on the industry landscape. In May 2017, Abbott recalled three balloon catheters due to difficulty removing the balloon sheath, resulting in 19 reports of injury and one death. This is a potential restraint hindering the global Drug-Eluting Balloon Catheters Market growth.
Global Drug-Eluting Balloon Catheters Market Segmental
The report analyses the global Drug-Eluting Balloon Catheters Market based on product, end-user, and region.

Global Drug-Eluting Balloon Catheters Market by 

Based on product, it is bifurcated into coronary artery disease, and peripheral vascular disease. The coronary artery disease segment is expected to be the largest segment in the Drug-Eluting Balloon Catheters Market in 2021. The coronary artery disease DCB catheters segment is USD 510 million, owing to the rising prevalence of cardiac disorders worldwide. The product's use in the treatment of restenosis can also be attributed to the product's growth. Coronary artery disease DCB catheters are also commonly used for revascularization, assisting in the restoration of blood flow to blocked veins and arteries, further enhancing segmental growth.

Global Drug-Eluting Balloon Catheters Market by End-

Based on end-user, the Drug-Eluting Balloon Catheters Market is segmented into hospitals & clinics, ambulatory surgical centers, and catheterization laboratories. The ambulatory surgical centers segment dominated the market. The market for drug-eluting balloon catheters in ambulatory surgical centers is USD 400 million. This can be attributed to a shift in patient preference toward ambulatory surgical centers due to their affordability and high-quality treatment options. The incorporation of advanced equipment and technology at ASCs also contributes to the segment scenario. Several other critical factors, such as ASCs' ability to provide low-risk surgeries and more convenient treatment settings, are also boosting the segment's revenue.
Geographical Analysis of Global Drug-Eluting Balloon Catheters
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North America is dominating in the Drug-Eluting Balloon Catheters Market. North America drug-eluting balloon catheters market is poised to surpass USD 440 million, owing to rising occurrence of chronic disorders in the region. As per the National Institute of Diabetes and Digestive and Kidney Disease 2021 report, nearly 37 million people in America have chronic kidney disease, which accounts for 1 in 7 adults requiring catheterization for treatment. This is due to rising awareness, favorable government initiatives, and the region’s well-developed healthcare infrastructure.
Major Players in the Global Drug-Eluting Balloon Catheters Market
The key players studied in the global Drug-Eluting Balloon Catheters Market are B. Braun Melsungen AG, Medtronic, BD Interventional, Biotronik AG, Eurocor GmbH, MedAlliance, Boston Scientific Corporation, Lepu Medical Technology Co Ltd, iVascular S.L.U, and Cook Medical among others.
COVID-19 Impact
The COVID-19 pandemic and lockdown in various countries around the world has had a negative impact on businesses in all sectors. The COVID-19 pandemic has impacted the entire healthcare supply chain, owing to strict lockdown in several regions. Similarly, because of the delayed peripheral, interventional, and cardiovascular surgical procedures caused by the COVID-19 pandemic, the drug-eluting balloon catheters industry suffered greatly. Many countries prioritized the treatment of coronavirus patients in order to keep the system from becoming overburdened by the high case count. All non-emergency procedures, including catheterization, were also postponed in order to redirect resources to pandemic patient treatment and care.

However, demand for drug-eluting balloon catheters is expected to skyrocket in the post-pandemic era. Despite the fact that the pandemic caused a significant drop in sales, the market has recovered the losses in the coming years as research accelerates.
Recent Developments

In February 2022, Boston Scientific Corporation, has acquired Baylis Medical Company Inc., in order to broaden its geographic footprint, target new markets, and generate revenue.
In July 2021, following the CE (Conformité Européene) mark, Medtronic plc, launched the Prevail drug coated balloon Catheter in Europe. The Prevail DCB is a coronary DCB that is currently available on the market. It is used during percutaneous coronary intervention procedures to treat narrowed/blocked coronary arteries in patients with coronary artery disease. The balloon is inflated within the artery during the catheter-based procedure, and the drug is delivered to the arterial tissue, where it is absorbed.
In March 2021, MedAlliance announced that its drug-eluting coronary balloon had been approved by the FDA. The Selution SLR sustained limus release drug-eluting balloon catheter is the name of the product. It was approved for its design, which increased luminal diameter in people with atherosclerotic lesions.
In February 2021, six products from L2Mtech GmbH have received their first CE mark. This is a watershed moment in the company's history, demonstrating the efficacy and safety of its cutting-edge cardiovascular and endovascular applications. The company intends to commercialize the products with CE mark recognition.
On June 2020, the medical device company iVascular SLU has announced the global launch of its novel coronary artery drug-coated balloon. The Essential Pro product has several improvements over its previous product.

Frequently Asked Questions
Q1. How big is the Drug-Eluting Balloon Catheters Market?

Ans. The global Drug-Eluting Balloon Catheters Market size was US$ 400 million in 2021 and is anticipated to reach US$ 1.1 billion in 2031, growing at a rate of 10.7% from 2022 to 2031.

Q2. What is the Drug-Eluting Balloon Catheters Market growth rate?

Ans. The growth rate of the Drug-Eluting Balloon Catheters Market is 10.7% from 2022 to 2031.

Q3. Which region holds a major market share for the Drug-Eluting Balloon Catheters Market?

Ans. The North America holds a major market share of the Drug-Eluting Balloon Catheters Market in 2021.

Q4. Which segment accounted for the largest Drug-Eluting Balloon Catheters Market share?

Ans. Based on product, it is bifurcated into coronary artery disease, and peripheral vascular disease. The coronary artery disease segment is expected to be the largest segment in the Drug-Eluting Balloon Catheters Market in 2021.

Q5. Who are the key players in the Drug-Eluting Balloon Catheters Market?

Ans. The global Drug-Eluting Balloon Catheters Market report includes players such as B. Braun Melsungen AG, Medtronic, BD Interventional, Biotronik AG, Eurocor GmbH, MedAlliance, Boston Scientific Corporation, Lepu Medical Technology Co Ltd, iVascular S.L.U, and Cook Medical among others.

Q6. What are the factors driving the Drug-Eluting Balloon Catheters Market growth?

Ans. The major factors driving the growth of the market are the increasing prevalence of coronary artery disease and increasing prevalence of diabetes.

Q7. What are the key growth strategies of Drug-Eluting Balloon Catheters Market players?

Ans. The key growth strategies of Drug-Eluting Balloon Catheters Market players are product launch, partnerships, and government initiatives.

Q8. Which region will provide more business opportunities for the Drug-Eluting Balloon Catheters Market during the forecast period?

Ans. The North America will provide more business opportunities for the Drug-Eluting Balloon Catheters Market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.